Loading clinical trials...

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

NCT04567615•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
•Must have advanced/metastatic HCC
•Have to be immunotherapy treatment-naive in the advanced/metastatic setting
•Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
•Child-Pugh score of 5 or 6
•Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale

Exclusion Criteria

•Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
•Prior organ allograft or allogeneic bone marrow transplantation
•No uncontrolled or significant cardiovascular disease
•No active known autoimmune disease
•Have received one or two lines of tyrosine kinase inhibitor therapies
•Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy

Locations (65)

Local Institution - 0010

Ciudad de Buenos Aires, Buenos Aires, Argentina

Local Institution - 0019

Buenos Aires, Distrito Federal, Argentina

Local Institution - 0017

Rosario, Santa Fe Province, Argentina

Local Institution - 0063

San Miguel de Tucumán, Tucumán Province, Argentina

Local Institution - 0025

Belo Horizonte, Minas Gerais, Brazil

Local Institution - 0060

Porto Alegre, Rio Grande do Sul, Brazil

Local Institution - 0016

Barretos, São Paulo, Brazil

Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology

Ribeirão Preto, São Paulo, Brazil

Local Institution - 0015

São Paulo, São Paulo, Brazil

Local Institution - 0024

Temuco, Región de la Araucanía, Chile

Key Dates

Start Date

February 4, 2021

Primary Completion Date

August 31, 2023

Completion Date

November 19, 2025

Last Updated

January 8, 2026

Enrollment

266

ACTUAL participants

Conditions

Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell CarcinomaLiver Cell Carcinoma, Adult

Interventions

Nivolumab

BIOLOGICAL

Relatlimab

BIOLOGICAL

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITING

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Early Detection of Liver Cancer by QUS

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)